Navigation Links
The current state of lung cancer treatment
Date:12/11/2012

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

"We're in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure," Bunn says.

The review describes the shift from blanketing lung cancer with radiation and chemotherapy, to targeting the specific genetic mutations that cause lung cancer's many varieties. The first of these oncogenic lung cancer mutations to be exploited by a drug was the epidermal growth factor receptor (EGFR), described in 2004 and targeted by the drugs erlotinib and gefitinib. Then in 2007 the oncogenic ALK/EML4 fusion protein was described, and is now targeted by the drug crizotinib, which earned FDA approval in 2011. Drugs in the development pipeline target a handful of additional lung-cancer-causing mutations including KRAS, HER2/neu, BRAF, NRAF, and ROS.

"Pathologists used to define lung cancer as one of four types, based on its appearance," Bunn says, "but it's much more heterogenous than that. Some of these driver mutations may only be present in 1 or 2 percent of the lung cancer population, and mutations in combination may make for hundreds of species of the disease, each with its own response characteristics to targeted drugs and drug combinations."

"Whole exome sequencing shows there are about 300 mutations in the average lung cancer," Bunn says. "You may have an EGFR mutation driving the cancer, but then the other 299 mutations may help define who will do well on an EGFR inhibitor."

Bunn points out that in the lung cancer varieties whose driver oncogenes can be matched with targeted therapy, we tend to see 70-80 percent patient response as opposed to 20-30 percent response to traditiona
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
2. Triple negative breast cancer symposium highlights current advances
3. Why current strategies for fighting obesity are not working
4. Current and former smokers at risk for recurrent hepatitis post-liver transplantation
5. DMP module on heart failure: Current guidelines indicate some need for revision
6. Study suggests new way to prevent recurrent ear infections
7. Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
8. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
9. Benefit of PET or PET/CT in recurrent bowel cancer is not proven
10. Study reveals how cancer drug causes diabetic-like state
11. New drug prevents spread of human prostate cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... TN (PRWEB) , ... September 01, 2015 , ... ... users to send information about new patients directly from Practice Perfect to FOTO ... duplicate data entry. , Steven Presement, President of Practice Perfect, ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of ... will take a look at the topic of arthritis. There are over 100 different ... explore interesting arthritis types and statistics in an effort to shed light on this ...
(Date:9/1/2015)... ... September 01, 2015 , ... Curly Hair ... hair salons. This highly anticipated partnership between Curly Hair Solutions™ and Trade Secrets ... Founder Jonathan Torch and the Curly Hair Solutions™ team could not be more ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces that ... Influence by Modern Luxury’s The Atlantan Magazine. , This award for the ... King. Her idea and vision to bring to Atlanta a true luxury experience ...
(Date:8/31/2015)... ... ... to undergoing a hair transplant, most patients have donor hair moved from one part of ... on top of the scalp, as well as filling in areas missing hair, is a ... areas of their head. , What about patients who have a limited, or even depleted, ...
Breaking Medicine News(10 mins):Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2
... Boston Scientific Corporation (NYSE: BSX ) today announced financial results ... for net sales and earnings per share (EPS) for the second quarter ... growth rates are constant currency): , , ... EPS of $0.19, both in line with guidance (GAAP loss per share ...
... should start with "evidence-based reimbursement", structuring physician payment ... which would improve quality and reduce the cost ... cardiologists and published in Circulation: Cardiovascular Quality ... example, some 500,000 U.S. patients suffering from mild ...
... San Diego was named a 2009 Clean Air Circle Honoree ... their annual Evening in the Sky Gala. Waste Management ... clean and ongoing efforts to protect the environment and promote ... working to promote clean air throughout San Diego, especially as ...
... needed economic boost to primary care services for Floridians ... Speaker Nancy Pelosi joined Rep. Debbie Wasserman Schultz today ... discuss the positive impact of the American Recovery and ... $10 million in federal stimulus money to fund eight ...
... glucose-based beverages may not have same impact, study finds ... drinks and other beverages can have a negative effect ... to handle fats, increasing the risk of heart attack ... glucose-sweetened beverages don,t have that kind of impact, the ...
... limits of procedure, study suggests , , MONDAY, April 20 ... removal of certain head and neck cancers, U.S. researchers ... cavity, throat or larynx tumors. Of those patients, 29 ... cancerous tissue. Negative margins (when no cancer cells are ...
Cached Medicine News:Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 2Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 3Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 4Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 5Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 6Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 7Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 8Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 9Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 10Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 11Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 12Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 13Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 14Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 15Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 16Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 17Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 18Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 19Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 20Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 21Health News:Health-care reform should start with paying evidence-based financial incentives to doctors 2Health News:Waste Management Honored by American Lung Association for Environmental Achievements 2Health News:Speaker Pelosi Visits Florida Health Center 2Health News:Robotic Surgery Practical for Some Head, Neck Tumors 2
(Date:9/1/2015)... September 1, 2015 BerGenBio AS ... announces that it has appointed Hilde Furberg ... to its Board of Directors, effective immediately. ... experience in pharma and biotech and is currently Senior ... company. Previously her role was Vice President and General ...
(Date:9/1/2015)... 1, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... that its affiliate has entered into a collaboration ... an exclusive license to develop and commercialize brodalumab. ... monoclonal antibody in development for patients with moderate-to-severe ... Valeant will hold the exclusive rights to develop ...
(Date:8/31/2015)... PHOENIX , Aug. 31, 2015  DICOM ... announced today that it was recognized as a ... Radiology software.  The awards are sponsored ... and related professionals in the medical imaging industry.  ... for radiology professionals to acknowledge the contributions of ...
Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2
... 2012   Syndax Pharmaceuticals, Inc. and Ventana Medical ... an agreement to develop a companion diagnostic assay to ... treatment with erlotinib and Syndax,s proprietary lead molecule entinostat.  ... Ventana, a world leader and innovator of tissue-based diagnostic ...
... (Nasdaq: VRNM ), a leading industrial biotechnology ... enzymes, today announced the introduction of VEREFLOW™ alpha-amylase, a ... drilling operations.  This high performance enzyme effectively removes filter ... on the face of the wellbore, the hole drilled ...
Cached Medicine Technology:Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat 2Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat 3Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat 4Verenium Launches Second Enzyme Product for Oilfield Services 2Verenium Launches Second Enzyme Product for Oilfield Services 3
FLEXILOG spare part....
Complete calibration kits are available for both pH and manometry systems....
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
... kit for convenient pH catheter calibration., ,pH ... any procedure. The Alpine Calibration kit contains ... water for your convenience. Simply cut the ... catheters to soak. No measuring or pouring! ...
Medicine Products: